Chemotherapy for hormonally refractory advanced prostate carcinoma: A comparison of combined versus sequential treatment with mitomycin C, doxorubicin, and 5-fluorouracil

J. A. Laurie, R. G. Hahn, Terry M Therneau, S. R. Patel, J. A. Mailliard, H. E. Windschitl, D. I. Twito, R. F. Morton, J. E. Krook

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

One hundred forty-two patients with progressive, hormonally refractory advanced prostate carcinoma who had not received prior chemotherapy were randomized to receive either combination chemotherapy with 5-fluorouracil (5- FU), doxorubicin, and mitomycin C (FAM) or sequential chemotherapy with the same agents, i.e., mitomycin C, followed by doxorubicin on disease progression, followed by 5-FU. Objective tumor regressions were observed in 10 of 70 (14%) patients receiving the FAM treatment arm and 10 of 72 (14%) patients initially receiving mitomycin C. Of the 24 patients who received secondary therapy with doxorubicin alone, 3 (12.5%) achieved objective tumor regression. There were no responses among five patients who received tertiary therapy with 5-FU alone. The median survival time for all patients treated with the combination arm was 8.7 months, compared with 7.1 months for patients who received the FAM arm (P = 0.025). However, this modest survival advantage in favor of the FAM treatment arm must be weighed against significantly more myelosuppression experienced by these patients. The chemotherapeutic regimens used in this study have only minor clinical value in the treatment of hormonally refractory advanced prostate cancer.

Original languageEnglish (US)
Pages (from-to)1440-1444
Number of pages5
JournalCancer
Volume69
Issue number6
StatePublished - 1992
Externally publishedYes

Fingerprint

Mitomycin
Fluorouracil
Doxorubicin
Prostate
Carcinoma
Drug Therapy
Therapeutics
Survival
Combination Drug Therapy
Disease Progression
Neoplasms
Prostatic Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Chemotherapy for hormonally refractory advanced prostate carcinoma : A comparison of combined versus sequential treatment with mitomycin C, doxorubicin, and 5-fluorouracil. / Laurie, J. A.; Hahn, R. G.; Therneau, Terry M; Patel, S. R.; Mailliard, J. A.; Windschitl, H. E.; Twito, D. I.; Morton, R. F.; Krook, J. E.

In: Cancer, Vol. 69, No. 6, 1992, p. 1440-1444.

Research output: Contribution to journalArticle

Laurie, JA, Hahn, RG, Therneau, TM, Patel, SR, Mailliard, JA, Windschitl, HE, Twito, DI, Morton, RF & Krook, JE 1992, 'Chemotherapy for hormonally refractory advanced prostate carcinoma: A comparison of combined versus sequential treatment with mitomycin C, doxorubicin, and 5-fluorouracil', Cancer, vol. 69, no. 6, pp. 1440-1444.
Laurie, J. A. ; Hahn, R. G. ; Therneau, Terry M ; Patel, S. R. ; Mailliard, J. A. ; Windschitl, H. E. ; Twito, D. I. ; Morton, R. F. ; Krook, J. E. / Chemotherapy for hormonally refractory advanced prostate carcinoma : A comparison of combined versus sequential treatment with mitomycin C, doxorubicin, and 5-fluorouracil. In: Cancer. 1992 ; Vol. 69, No. 6. pp. 1440-1444.
@article{3bcfe1e527534f8cb75eff2e9b8a9be1,
title = "Chemotherapy for hormonally refractory advanced prostate carcinoma: A comparison of combined versus sequential treatment with mitomycin C, doxorubicin, and 5-fluorouracil",
abstract = "One hundred forty-two patients with progressive, hormonally refractory advanced prostate carcinoma who had not received prior chemotherapy were randomized to receive either combination chemotherapy with 5-fluorouracil (5- FU), doxorubicin, and mitomycin C (FAM) or sequential chemotherapy with the same agents, i.e., mitomycin C, followed by doxorubicin on disease progression, followed by 5-FU. Objective tumor regressions were observed in 10 of 70 (14{\%}) patients receiving the FAM treatment arm and 10 of 72 (14{\%}) patients initially receiving mitomycin C. Of the 24 patients who received secondary therapy with doxorubicin alone, 3 (12.5{\%}) achieved objective tumor regression. There were no responses among five patients who received tertiary therapy with 5-FU alone. The median survival time for all patients treated with the combination arm was 8.7 months, compared with 7.1 months for patients who received the FAM arm (P = 0.025). However, this modest survival advantage in favor of the FAM treatment arm must be weighed against significantly more myelosuppression experienced by these patients. The chemotherapeutic regimens used in this study have only minor clinical value in the treatment of hormonally refractory advanced prostate cancer.",
author = "Laurie, {J. A.} and Hahn, {R. G.} and Therneau, {Terry M} and Patel, {S. R.} and Mailliard, {J. A.} and Windschitl, {H. E.} and Twito, {D. I.} and Morton, {R. F.} and Krook, {J. E.}",
year = "1992",
language = "English (US)",
volume = "69",
pages = "1440--1444",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "6",

}

TY - JOUR

T1 - Chemotherapy for hormonally refractory advanced prostate carcinoma

T2 - A comparison of combined versus sequential treatment with mitomycin C, doxorubicin, and 5-fluorouracil

AU - Laurie, J. A.

AU - Hahn, R. G.

AU - Therneau, Terry M

AU - Patel, S. R.

AU - Mailliard, J. A.

AU - Windschitl, H. E.

AU - Twito, D. I.

AU - Morton, R. F.

AU - Krook, J. E.

PY - 1992

Y1 - 1992

N2 - One hundred forty-two patients with progressive, hormonally refractory advanced prostate carcinoma who had not received prior chemotherapy were randomized to receive either combination chemotherapy with 5-fluorouracil (5- FU), doxorubicin, and mitomycin C (FAM) or sequential chemotherapy with the same agents, i.e., mitomycin C, followed by doxorubicin on disease progression, followed by 5-FU. Objective tumor regressions were observed in 10 of 70 (14%) patients receiving the FAM treatment arm and 10 of 72 (14%) patients initially receiving mitomycin C. Of the 24 patients who received secondary therapy with doxorubicin alone, 3 (12.5%) achieved objective tumor regression. There were no responses among five patients who received tertiary therapy with 5-FU alone. The median survival time for all patients treated with the combination arm was 8.7 months, compared with 7.1 months for patients who received the FAM arm (P = 0.025). However, this modest survival advantage in favor of the FAM treatment arm must be weighed against significantly more myelosuppression experienced by these patients. The chemotherapeutic regimens used in this study have only minor clinical value in the treatment of hormonally refractory advanced prostate cancer.

AB - One hundred forty-two patients with progressive, hormonally refractory advanced prostate carcinoma who had not received prior chemotherapy were randomized to receive either combination chemotherapy with 5-fluorouracil (5- FU), doxorubicin, and mitomycin C (FAM) or sequential chemotherapy with the same agents, i.e., mitomycin C, followed by doxorubicin on disease progression, followed by 5-FU. Objective tumor regressions were observed in 10 of 70 (14%) patients receiving the FAM treatment arm and 10 of 72 (14%) patients initially receiving mitomycin C. Of the 24 patients who received secondary therapy with doxorubicin alone, 3 (12.5%) achieved objective tumor regression. There were no responses among five patients who received tertiary therapy with 5-FU alone. The median survival time for all patients treated with the combination arm was 8.7 months, compared with 7.1 months for patients who received the FAM arm (P = 0.025). However, this modest survival advantage in favor of the FAM treatment arm must be weighed against significantly more myelosuppression experienced by these patients. The chemotherapeutic regimens used in this study have only minor clinical value in the treatment of hormonally refractory advanced prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=0026515856&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026515856&partnerID=8YFLogxK

M3 - Article

C2 - 1540881

AN - SCOPUS:0026515856

VL - 69

SP - 1440

EP - 1444

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 6

ER -